painreform is a specialty pharmaceutical company that develops products for the treatment of pain. focused on reformulations of established pain drugs for the us fda 505(b)(2) regulatory pathway, painreform applies unique technologies to enhance efficacy, reduce adverse effects and increase convenience. our mission is to offer pain therapeutics with clinically meaningful benefits to both physicians and patients.
PainReform (Nasdaq: PRFX) is advancing its OcuRing-K intraoperatively administered ocular device towards a Phase II clinical trial for post-cataract pain and inflammation. This device, developed by LayerBio, aims to replace multi-week eye-drop regimens by delivering controlled ketorolac release and targets the substantial global cataract surgery market, estimated at $9 billion annually. Preclinical studies and a Phase I evaluation have shown reduced pain and inflammation with lower total drug exposure, positioning OcuRing-K as a potential "drop-less" solution to simplify postoperative care.
PainReform Ltd. has initiated the development plan for OcuRing-K, a novel sustained-release ocular therapy for post-cataract surgery pain and inflammation, aiming to eliminate the need for traditional eye drops. This therapy, integrated after PainReform's majority investment in LayerBio, showed promising results in preclinical studies and a Phase I clinical evaluation. The company seeks to advance OcuRing-K through further clinical development, targeting a significant global surgical market.
PainReform Ltd. has initiated the development plan for OcuRing-K, LayerBio's sustained-release ocular therapy, moving it towards a Phase II clinical trial. This drop-less device is designed for controlled delivery of ketorolac after cataract surgery, aiming to reduce post-surgical pain and inflammation with lower total drug exposure. The technology also has potential for delivering other ophthalmic therapeutics, aligning with PainReform's future expansion plans.
PainReform Ltd. (Nasdaq: PRFX) announced the start of its development plan for OcuRing™-K, LayerBio's patented, drop-less, sustained-release ocular therapy, moving towards Phase II clinical trials. This therapy is designed to deliver ketorolac following cataract surgery, addressing the limitations of traditional eye-drop regimens with a single, intraoperative application. The company aims to provide consistent pain and inflammation control with lower drug exposure, targeting the multi-billion-dollar global cataract surgery market.
PainReform Ltd. announced it will hold its Annual General Meeting of Shareholders on December 30, 2025, at 3:00 p.m. Israel time, in Tel Aviv. Shareholders will vote on proposals outlined in a distributed Notice and Proxy Statement, with options to vote in person or by proxy. This meeting provides an opportunity for shareholders to participate in the company's governance.
Acceptance to NVIDIA Connect Program offers access to unique tools for the development of DeepSolar's nextgen, AI-driven, solar forecasting platform to improve weather prediction accuracy by up to 50% and optimize energy asset performance Acceptance to NVIDIA Connect Program offers access to ...
All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.